Recent News

• 12.10.2025 - Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology
• 11.12.2025 - Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
• 11.05.2025 - Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025
• 10.24.2025 - Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference
• 10.08.2025 - Journey Medical Corporation to Participate in October 2025 Investor Conferences
• 09.03.2025 - Journey Medical Corporation to Participate in September 2025 Investor Conferences
• 08.18.2025 - Journey Medical Corporation to Present at the Emerging Growth Conference
• 08.12.2025 - Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
• 08.07.2025 - Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11

Recent Filings

• 11.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.12.2025 - 8-K Current report
• 11.12.2025 - EX-99.1 EX-99.1
• 09.26.2025 - 8-K Current report
• 08.28.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 08.28.2025 - 8-K Current report
• 08.26.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.12.2025 - EX-99.1 EX-99.1
• 08.12.2025 - 8-K Current report